This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): anidulafungin, Ecalta (EU), LY303366
Description: Anidulafungin is a naturally occurring molecule that has been significantly improved through chemical modification. It is a member of the class of anti-fungal drugs known as the echinocandins: its mechanism of action is by inhibition of (1,3)ß-D-glucan synthase, which is an important component of the fungal cell wall.
In vitro studies have demonstrated that anidulafungin combines both the potency and killing effects of the polyene class (e.g., amphotericin B) without the resistance problems found with the azole class (e.g., fluconazole). Anidulafungin is a broad-spectrum agent, and has been demonstrated to be highly potent in vitro against candida and aspergillus, fungi responsible for serious systemic infections. Preclinical studies have shown that a five-minute exposure to anidulafungin in vitro kills more than 99 % of Candida, including fluconazole-resistant strains. Anidulafungin has no cross-resistance with azoles or amphotericin, and in the laboratory it has proven very difficult to develop resistance to anidulafungin.
Deal Structure: In September 2005, Pfizer completed its acquisition of Vicuron Pharmaceuticals. Through the transaction, Pfizer acquired anidulafungin.
In July 2008, Pfizer Nagoya Laboratories was relaunched as a fully independent company, RaQualia Pharma, which will have Japan-only licensing rights for development and commercialization of Eraxis (Anidulafungin).
Partners: RaQualia Pharma Inc.
Pink Sheet Pfizer Eraxis pricing
Additional information available to subscribers only: